Billiontoone (NASDAQ:BLLN) Research Coverage Started at Guggenheim

Guggenheim began coverage on shares of Billiontoone (NASDAQ:BLLN) in a report issued on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $120.00 price objective on the stock.

BLLN has been the subject of several other research reports. Zacks Research upgraded shares of Billiontoone to a “hold” rating in a research report on Tuesday, December 2nd. Wall Street Zen raised Billiontoone to a “hold” rating in a report on Saturday, November 15th. William Blair initiated coverage on Billiontoone in a research report on Monday, December 1st. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. reduced their price target on Billiontoone from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Wednesday, December 10th. Finally, Stifel Nicolaus assumed coverage on Billiontoone in a research note on Monday, December 1st. They issued a “buy” rating and a $145.00 price target for the company. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Billiontoone presently has an average rating of “Moderate Buy” and an average target price of $135.29.

Billiontoone Stock Down 2.1%

Shares of BLLN opened at $87.59 on Tuesday. Billiontoone has a 12 month low of $80.51 and a 12 month high of $138.70. The firm has a market cap of $4.01 billion and a P/E ratio of 875.90.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Tuesday, December 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.06). The firm had revenue of $83.52 million for the quarter, compared to the consensus estimate of $82.86 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Billiontoone stock. Green Alpha Advisors LLC bought a new position in shares of Billiontoone, Inc. (NASDAQ:BLLN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 5,326 shares of the company’s stock, valued at approximately $436,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.